EGFR exon 19 deletions: the deletion that drugs love

If you sequence a hundred EGFR-mutant lung tumors, the single most common thing you will find is not a point mutation at all. It is a short, in-frame deletion in exon 19 — usually the loss of the residues LREA at positions 747–750. Exon 19 deletions account for roughly 45–50% of EGFR-driven non-small cell lung cancer, edging out the exon 21 point mutation L858R. They are also, drug for drug, the most inhibitor-sensitive class of EGFR mutations we know how to treat.

What “exon 19 deletion” actually means

Exon 19 encodes part of the N-lobe of the EGFR kinase domain, including the short loop that connects the β3 strand to the regulatory αC helix. The deletions cluster around residues 746–753 and remove three to seven amino acids while keeping the reading frame intact. The textbook variant is ΔE746_A750 (the ELREA deletion), but ex19del is really a family: E746_A750del, L747_P753delinsS, E746_S752delinsV, and a dozen rarer cousins. They are reported together because they converge on the same structural trick.

Why losing residues turns the kinase on

Counterintuitively, deleting amino acids makes the kinase more active. The β3–αC loop normally has slack in it, and that flexibility lets the αC helix swing outward into the inactive “αC-out” conformation where catalysis is switched off. Shortening the loop pulls the helix inward and rigidifies it in the active “αC-in” position. In that state the catalytic K745–E762 salt bridge is preformed, ATP binds more favorably than in wild-type, and the kinase signals without waiting for the receptor to dimerize at the cell surface. Molecular dynamics studies of the ΔELREA mutant show exactly this: stabilization of the αC-in state and a more favorable computed ATP-binding free energy than wild-type EGFR.

That same conformational bias is why inhibitors designed to recognize the active kinase tend to grip ex19del tightly. The mutation does not reshape the ATP pocket so much as it pre-pays the energetic cost of getting into the conformation those drugs prefer.

The drugs that hit it

• Gefitinib and erlotinib — first-generation reversible inhibitors. Ex19del tumors were where these drugs first proved that EGFR-mutant lung cancer is its own disease, with response rates well above what chemotherapy delivered.
• Afatinib and dacomitinib — second-generation irreversible binders that form a covalent bond to Cys797. Afatinib carries a specific approval signal in the common ex19del/L858R population.
• Osimertinib (Tagrisso) — third-generation, mutant-selective, and now the first-line standard of care for both common activating mutations.

What the trial data actually show

The pivotal FLAURA trial randomized untreated patients with common EGFR mutations to osimertinib versus a first-generation TKI. Across the whole population osimertinib nearly doubled median progression-free survival (18.9 versus 10.2 months). The split by mutation type is the part worth remembering: the exon 19 deletion subgroup did consistently better than the L858R subgroup, with median overall survival in ex19del patients landing north of 40 months. The structural intuition lines up with the clinic — a driver that is locked into the active, drug-preferred conformation is a driver you can suppress for longer.

Where resistance goes next

Ex19del does not stay alone forever. On osimertinib the dominant on-target escape is C797S, which removes the cysteine the covalent warhead depends on, and the order in which C797S and T790M appear (cis versus trans) decides whether any current EGFR inhibitor can still reach the target. Off-target bypass through MET amplification is the other common exit. Understanding the ex19del starting point is what makes that resistance ladder legible.

Try the docking yourself

Open Studio and pick EGFR with an exon 19 deletion to dock candidate inhibitors against the activated kinase. Because ex19del biases the conformational equilibrium toward the active αC-in state, it is a good case for comparing poses against wild-type and L858R structures side by side. Liganx brings molecular docking online into the browser, so you can run molecular docking against ex19del and read the binding-mode differences without installing anything.

Primary sources

• Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation. PLoS One 14, e0222814 (2019). doi:10.1371/journal.pone.0222814
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378, 113–125 (2018). doi:10.1056/NEJMoa1713137
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382, 41–50 (2020). doi:10.1056/NEJMoa1913662